Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial.
Lucas V.A. Boersma,Hueseyin Ince,Stephan Kische,Evgeny Pokushalov,Thomas Schmitz,Boris Schmidt,Tommaso Gori,Felix Meincke,Alexey Vladimir Protopopov,Timothy R. Betts,David P. Foley,Horst Sievert,Patrizio Mazzone,Tom De Potter,Elisa Vireca,Kenneth M. Stein,Martin Bergmann +16 more
Reads0
Chats0
TLDR
This method of stroke risk reduction appears to be safe and effective with an ischemic stroke rate as low as 1.1%, even though 73% of patients had a contraindication to and were not using oral anticoagulation.About:
This article is published in Heart Rhythm.The article was published on 2017-09-01 and is currently open access. It has received 301 citations till now. The article focuses on the topics: Stroke & Atrial fibrillation.read more
Citations
More filters
Journal ArticleDOI
Percutaneous left atrial appendage closure with complex anatomy by using the staged 'kissing-Watchman' technology with double devices.
Lisheng Jiang,Erich Duenninger,Manuela Muenzel,Xin Xue,Adam Fazakas,Thorsten Keil,Jiangtao Yu +6 more
TL;DR: The staged 'kissing-Watchman' technology is feasible and safe, which might provide a strategy to occlude the LAA with complex anatomy when an incomplete closure is inevitable with a single device.
Journal ArticleDOI
Long-term transesophageal echocardiography follow-up after percutaneous left atrial appendage closure
Stephan Staubach,Leonhard Schlatterbeck,Moritz Mörtl,Henning Strohm,Petra Hoppmann,Karl-Ludwig Laugwitz,Harald Mudra,Jakob Ledwoch +7 more
TL;DR: Peri-device leaks and device thrombi continue to occur during long-term follow-up following LAAO and the clinical impact of these late occluder complications requires further evaluation in larger prospective trials.
Journal ArticleDOI
Initial and long-term antithrombotic therapy after left atrial appendage closure with the WATCHMAN
Jakob Ledwoch,Kolja Sievert,Lucas V.A. Boersma,Martin Bergmann,Hüseyin Ince,Stephan Kische,Evgeny Pokushalov,Thomas Schmitz,Boris Schmidt,Tommaso Gori,Felix Meincke,Alexey Vladimir Protopopov,Timothy R. Betts,Patrizio Mazzone,David P. Foley,Marek Grygier,Tom De Potter,Horst Sievert +17 more
TL;DR: Tailored antithrombotic treatment using even very reduced strategies such as SAPT or no therapy showed no significant differences regarding ischaemic complications after LAA closure.
Journal ArticleDOI
Kidney function stratified outcomes of percutaneous left atrial appendage occlusion in patients with atrial fibrillation and high bleeding risk
Maximilian Brockmeyer,Georg Wolff,T Krieger,Yingfeng Lin,Athanasios Karathanos,Shazia Afzal,Tobias Zeus,Ralf Westenfeld,Amin Polzin,Yvonne Heinen,Stefan Perings,Malte Kelm,Volker Schulze +12 more
TL;DR: Left atrial appendage occlusion shows comparable efficacy for stroke and bleeding prevention in CKD and Non-CKD patients.
Journal ArticleDOI
Left Atrial Appendage Occlusion: The Current Device Landscape and Future Perspectives.
Ignacio Cruz-González,Monica Fuertes-Barahona,Jose Carlos Moreno-Samos,Rocío González-Ferreiro,Yan Yin Lam,Pedro L. Sánchez +5 more
TL;DR: The design, characteristics, and clinical data of the most frequently used devices for LAAO are reviewed, including the Amplatzer cardiac plug and Amulet, the Watchman, and the LARIAT device (SentreHEART).
References
More filters
Journal ArticleDOI
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof,Stefano Benussi,Dipak Kotecha,Anders Ahlsson,Dan Atar,Barbara Casadei,Manuel Castellá,Hans-Christoph Diener,Hein Heidbuchel,Jeroen M.L. Hendriks,Gerhard Hindricks,Antonis S. Manolis,Jonas Oldgren,Bogdan A. Popescu,Ulrich Schotten,Bart P. Van Putte,Panagiotis Vardas,Stefan Agewall,John Camm,Gonzalo Barón Esquivias,Werner Budts,Scipione Carerj,Filip Casselman,Antonio Coca,Raffaele De Caterina,Spiridon Deftereos,Dobromir Dobrev,José M. Ferro,Gerasimos Filippatos,Donna Fitzsimons,Bulent Gorenek,Maxine Guenoun,Stefan H. Hohnloser,Philippe Kolh,Gregory Y.H. Lip,Athanasios J. Manolis,John J.V. McMurray,Piotr Ponikowski,Raphael Rosenhek,Frank Ruschitzka,Irina Savelieva,Sanjay Sharma,Piotr Suwalski,Juan Tamargo,Clare J Taylor,Isabelle C. Van Gelder,Adriaan A. Voors,Stephan Windecker,José Luis Zamorano,Katja Zeppenfeld +49 more
TL;DR: The Task Force for the management of atrial fibrillation of the European Society of Cardiology has been endorsed by the European Stroke Organisation (ESO).
Journal ArticleDOI
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO)
Journal ArticleDOI
Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium
Roxana Mehran,Sunil V. Rao,Deepak L. Bhatt,C. Michael Gibson,Adriano Caixeta,John W. Eikelboom,Sanjay Kaul,Stephen D. Wiviott,Venu Menon,Eugenia Nikolsky,Victor L. Serebruany,Marco Valgimigli,Pascal Vranckx,David P. Taggart,Joseph F. Sabik,Donald E. Cutlip,Mitchell W. Krucoff,E. Magnus Ohman,Philippe Gabriel Steg,Harvey D. White +19 more
TL;DR: Bleeding complications have been associated with an increased risk of subsequent adverse outcomes, including MI, stroke, stent thrombosis, and death, in patients with ACS and in those undergoing percutaneous coronary intervention (PCI) as well as in the long-term antithrombotic setting.
Journal ArticleDOI
Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation
TL;DR: Data suggest that left atrial appendage obliteration is a strategy of potential value for stroke prophylaxis in nonrheumatic atrial fibrillation.
Journal ArticleDOI
Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREVAIL Trial
David R. Holmes,Saibal Kar,Matthew J. Price,Brian Whisenant,Horst Sievert,Shephal K. Doshi,Kenneth C. Huber,Vivek Y. Reddy +7 more
TL;DR: In this trial, LAA occlusion was noninferior to warfarin for ischemic stroke prevention or SE >7 days' post-procedure in patients with NVAF who do not have an absolute contraindication to short-termwarfarin therapy.
Related Papers (5)
Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof,Stefano Benussi,Dipak Kotecha,Anders Ahlsson,Dan Atar,Barbara Casadei,Manuel Castellá,Hans-Christoph Diener,Hein Heidbuchel,Jeroen M.L. Hendriks,Gerhard Hindricks,Antonis S. Manolis,Jonas Oldgren,Bogdan A. Popescu,Ulrich Schotten,Bart P. Van Putte,Panagiotis Vardas,Stefan Agewall,John Camm,Gonzalo Barón Esquivias,Werner Budts,Scipione Carerj,Filip Casselman,Antonio Coca,Raffaele De Caterina,Spiridon Deftereos,Dobromir Dobrev,José M. Ferro,Gerasimos Filippatos,Donna Fitzsimons,Bulent Gorenek,Maxine Guenoun,Stefan H. Hohnloser,Philippe Kolh,Gregory Y.H. Lip,Athanasios J. Manolis,John J.V. McMurray,Piotr Ponikowski,Raphael Rosenhek,Frank Ruschitzka,Irina Savelieva,Sanjay Sharma,Piotr Suwalski,Juan Tamargo,Clare J Taylor,Isabelle C. Van Gelder,Adriaan A. Voors,Stephan Windecker,José Luis Zamorano,Katja Zeppenfeld +49 more